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After graduating from high school in my 
hometown of Le Mars, Iowa, I had a stint in 
the US Navy (1944–1945), earned a BA degree 
from Westminster College in Missouri (1947) 
and completed two years of medical school at 
Northwestern University (1947–1949). I then 
dropped out to do research in neurophysiol-
ogy under the inspiring tutelage of Horace W. 
Magoun, first at Northwestern and subsequently 
at the then-new medical school of the University 
of California, Los Angeles. With MD and PhD 
degrees from Northwestern, I served a one-year 
internship at Johns Hopkins Hospital before 
doing a full-time, 18-month study of complete 
heart block, which was a frequent complication 
with the first human open-heart operations. The 
experiments involved creation of a canine model 
of heart block and treatment of its adverse con-
sequences with repetitive low-voltage ventricu-
lar stimulation—the first epicardial pacemaking.
The experimental transplant models
After I returned to my duties as a surgical resi-
dent (1954–1959), discussions with surgical 
colleagues about the liver’s double-blood supply 
prompted my spare-time development of canine 
models of abdominal organ transplant. The 
question was whether hormone- and nutrient- 
rich portal blood was important for optimal 
total-body metabolism and, specifically, for 
liver health. This subject had been unresolved 
for nearly 80 years because of the confusing lit-
erature on portacaval shunt (Eck’s fistula). The 
canine model of auxiliary liver transplantation 
described in 1955 by C. Stuart Welch at Albany 
Medical College epitomized the controversy. 
While leaving the blood supply of the native 
liver intact, Welch arterialized the extra liver 
(an allograft) but provided its portal inflow with 
systemic venous return from the lower part of 
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the body (Fig. 1a). The dramatic shrinkage of 
the transplanted liver was attributed to rejec-
tion. My alternative explanation was that the 
allograft had been deprived of liver-supporting 
(hepatotrophic) factors in the portal blood.
In 1958–1959, I developed two procedures 
to test this hypothesis. One was liver replace-
ment1 (Fig. 1b). The other was removal of the 
liver and all the other intra-abdominal organs 
and replacement of them with a multivisceral 
allograft2 (Fig. 1c). The three models in com-
bination generated parallel avenues of research. 
The first concerned the metabolic cross- 
regulation of the different abdominal organs 
and, in particular, the importance of their 
relative anatomic positions. By showing that 
endogenous insulin and other molecules in 
portal blood play a crucial part in the control 
of the liver’s size, ultrastructure, function and 
capacity for regeneration3, the hepatotrophic 
research contributed importantly to the scien-
tific basis of liver transplantation and filled in 
present and future gaps throughout hepatology 
and regenerative medicine.
Human organ transplantation
Despite the intrinsic scientific interest of the 
transplant operations, their use as a treat-
ment for human liver diseases was the domi-
nant theme in my laboratory and in clinical 
research from 1958 onward. Unbeknownst 
to me, 1958 also marked the start of similar 
efforts by Francis D. Moore at the Peter Bent 
Brigham Hospital (now Brigham and Women’s 
Hospital) in Boston. At the time, the only evi-
dence that rejection might be avoidable came 
from epochal experiments done by Rupert 
Billingham, Leslie Brent and Peter Medawar 
in 1953, in which allogeneic spleen cells were 
transplanted into immunologically imma-
ture mice. This model presaged bone marrow 
transplantation in immunodeficient humans. In 
a second model, which heralded clinical bone 
marrow transplantation for a wide range of 
other indications, Joan M. Main and Richmond 
T. Prehn reduced the immune responsiveness of 
adult mice with irradiation before transplant-
ing donor lymphoid cells. In both mouse mod-
els, animals permanently bearing donor cells 
(donor leukocyte chimerism) could accept 
tissues from the original donor but not from 
others (donor-specific tolerance).
The feasibility of the mouse tolerance mod-
els required a close match between donor and 
recipient tissue (histocompatibility) antigens. 
Otherwise, the donor cells would be rejected 
or cause graft-versus-host disease. Because it 
was another 15 years before enough human 
leukocyte antigens had been discovered to 
permit donor-recipient matching, clinical bone 
marrow transplantation was not accomplished 
until 1968. In contrast, during the 1959–1962 
time frame of my liver model development, kid-
ney allografts were successfully transplanted in 
seven sublethally irradiated human recipients, 
without tissue matching and in the ostensible 
absence of donor leukocytes (Table 1). These 
patients were rare exceptions to the usual out-
come of transplant rejection and patient death, 
but they made the concept of liver replacement 
in humans seem less remote.
In the next step, Joseph Murray at Peter 
Bent Brigham transplanted a kidney into a 
patient who had not received irradiation and 
achieved graft function for 17 months under 
daily treatment with azathioprine, a drug that 
Roy Calne (with Murray) and Charles Zukoski 
(with David Hume in Richmond, Virginia) 
had preclinically tested. Enthusiasm for such 
pharmacological immunosuppression waned 
when the case was an isolated success. By then 
(early 1962), I had obtained a supply of aza-
thioprine for evaluation alone or with other 
agents in canine transplant models. When we 
stopped treatment at 100 days in the dogs that 
had survived that long, many of the liver recipi-
ents and an occasional kidney recipient did not 
reject their grafts. Although rare, these precious 
dogs contributed to the confidence with which 
we launched human kidney and liver programs 
(in that order) at the University of Colorado, 
Denver. However, more substantive reassurance 
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Swept up by the momentum of our successes 
with kidneys, we attempted five human liver 
replacements between March and October of 
1963, using the same immunosuppression but 
foreshortening pretreatment4. Maximum sur-
vival was 23 days. All but one of the hepatic 
grafts functioned throughout, and we found 
little evidence at autopsy of rejection or pres-
ervation injury. Instead, death was caused by 
infections at multiple sites. In the lung, these 
were associated with pulmonary emboli, which 
formed in and migrated from the venovenous 
bypasses that had been an essential component 
of the canine liver operation. After two more 
failed attempts, one in Boston (by Moore) and 
the other in Paris, all human liver-transplant 
activity ceased worldwide until the summer of 
1967. The procedure had come to be perceived 
as too difficult to ever be tried again.
During the moratorium, we addressed 
problems that contributed to the 1963 failures, 
after rejection reversal. For example, the third 
patient (Fig. 2a) is now the world’s longest- 
surviving kidney allograft recipient, at 49.5 
years after transplantation, and has been immu-
nosuppression free for the past quarter-century.
When that series was inaugurated in 1962, 
Murray’s long-standing kidney-transplant 
program at the Brigham was the only clinically 
active one in North America. Guided by freely 
shared data from the University of Colorado, 
David Hume established a third clinical pro-
gram, at the Medical College of Virginia (now 
Virginia Commonwealth University), in which 
azathioprine and prednisone were also used. 
During the next two years, nearly 50 renal cen-
ters were founded or were gearing up in the 
United States, and similar events were occur-
ring in Europe. The development of new centers 
was facilitated by my 1964 textbook Experience 
in Renal Transplantation, which was based on 
our lab experiments and research in humans.
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came from our reproducible observations in 
dogs, which had not been apparent under the 
testing conditions in other laboratories.
We used the Denver dog findings to design 
clinical protocols. We started human recipients 
of kidneys from living donors on a daily azathi-
oprine regimen several weeks before transplan-
tation, adding prednisone afterward to treat the 
rejections that almost invariably occurred. This 
incremental use of drugs exposed two features 
of the immune system that were generalizable 
to all kinds of transplanted organs. These fea-
tures made up the title of a report, published in 
the October 1963 issue of Surgery, Gynecology 
and Obstetrics (now the Journal of the American 
College of Surgeons), of the world’s first series 
of repetitively successful kidney transplanta-
tions: “The reversal of rejection in human 
renal homografts with subsequent develop-
ment of homograft tolerance.” Tolerance was 
inferred from a declining need for treatment 
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Figure 1  Three early approaches to liver transplantation. (a) Welch’s auxiliary liver transplantation in dogs. (b) Complete liver replacement in dog. The fact that 
the recipient was a dog rather than a human is identifiable only by the multi-lobar appearance of the liver. (c) Organs (blue) of a multivisceral graft in dogs or 
humans. Illustration by Jon Coulter, M.A., C.M.I.
Table 1  Characteristics of the first successful transplantations of kidney allografts with ≥6 months survival as of March 1963
Physician Site Date Donor Relationship Survival outcome
Joseph E. Murray Boston 24 January 1959 Fraternal twin 20 years
Jean Hamburgera Paris 29 June 1959 Fraternal twin 26 years
Rene Küssa Paris 22 June 1960 Unrelated 18 monthsb
Jean Hamburgera Paris 19 December 1960 Mother 22 monthsb
Rene Küssa Paris 12 March 1961 Unrelated 18 monthsb
Ralph Shackman London 26 March 1961 Brother 3 years
Jean Hamburgera Paris 12 February 1962 Cousin 15 yearsc
Joseph E. Murray Boston April 1962 Unrelated 17 monthsd
Thomas E. Starzl Denver 1962–1963 Mixed series 50 years
aKüss and Hamburger described periodic administration of adrenal cortical steroids with these patients.bPatient death occurred at listed time. cPatient underwent successful 
retransplantation in the 1970’s. dFirst success with drugs-only immunosuppression (no radiation).
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my colleagues and I established efficacy of the 
treatment for other transplanted vital organs. 
In December of 1981, the promising develop-
ments were reported to C. Everett Koop, who 
took office as US Surgeon General the following 
January. With personal and sustained encour-
agement from then-president Ronald Reagan, 
Koop initiated steps leading to a Consensus 
Development Conference for liver transplan-
tation that would be held by the US National 
Institutes of Health and include input from the 
four European centers.
On 23 June 1983, the consensus commit-
tee concluded that liver transplantation had 
become a “clinical service” rather than an 
transplantation in place today was developed 
through the transatlantic alliance of these five 
centers. All the while, the continued survival 
of brave forerunner liver recipients kept hope 
alive. The world’s longest-surviving recipient, 
who was treated for biliary atresia as a child, 
has now borne her transplanted liver for 42.7 
years (Fig. 2c).
Most of the indicators of transplant candidacy 
were obvious, including inheritable disorders 
with known liver-based biochemical explana-
tions (for example, Wilson’s disease). The lit-
mus test of liver transplantation itself ultimately 
helped to elucidate the mechanisms and patho-
physiology of some inborn errors of metabolism 
that were not as well understood: a-1-antitrypsin 
deficiency, glycogen-storage disorders and 
hyperlipoproteinemia. However, liver transplan-
tation remained ‘feasible but impractical’ until 
the advent of cyclosporine. In 1979, Roy Calne 
reported its use in 34 patients who had received 
transplants, two of whom were liver recipients. 
Cyclosporine was far more potent than azathio-
prine. However, its side effects caused its near 
abandonment until we combined it with pred-
nisone in our original two-drug protocol.
Kidney recipients were the first to benefit 
from our cyclosporine-prednisone regimen. 
Close behind, 11 of our first 12 liver recipi-
ents, treated during 1979–1980, survived for 
longer than one year7. In December of 1980, 
I moved from Colorado to Pittsburgh, where 
achieving control of blood coagulation, 
improved organ preservation, infection contain-
ment and avoidance when possible of venove-
nous bypasses. To improve immunosuppression, 
we refined antilymphocyte globulin from the 
serum of horses immunized against human 
lymphoid cells for use as an adjunct to azathio-
prine and prednisone. Equally important, liver-
graft availability was enhanced by the evolving 
general acceptance of brain death. Beginning in 
July 1967, multiple liver recipients survived for 
longer than one year (Fig. 2b) with the triple 
immunosuppression regimen of azathioprine, 
prednisone and antilymphocyte globulin5.
Over the next two years, my colleagues and 
I achieved enough successes to publish the 
1969 Experience in Hepatic Transplantation6, 
a companion textbook to my 1964 kidney 
book. By then, the first successful human heart 
transplants (in Cape Town, South Africa, and 
Palo Alto, California) and pancreas transplants 
(in Minneapolis) had been recorded, all using 
the three-drug immunosuppression regimen. 
However, a dozen more years passed before the 
promise of liver and other kinds of non-renal 
transplantation was fulfilled. Even so, four 
European liver centers were founded during 
this interval: the first by Roy Calne (Cambridge, 
UK) in 1968, followed by Henri Bismuth (Paris), 
Rudolf Pichlmayr (Hannover, Germany) and 
Rudi Krom (Gronigen, The Netherlands) dur-
ing the 1970s. Much of the framework of liver 
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Figure 2  Early successes of liver transplantation. (a) The world’s longest-surviving renal-allograft recipient at age 37 (top) and 86 (bottom) years. (b) The 
Swedish surgeon Carl Groth with three long-surviving liver recipients in Denver, 1967. (c) The world’s longest-surviving liver recipient, before (top left), 
shortly after (top right) and 42.7 years after (bottom) transplantation.
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Figure 3  Stepwise immunosuppression-
associated improvements in liver-transplant 
survival. Similar improvements subsequently 
occurred with other organs. AZA, azathioprine; 
CYA, cyclosporine; TAC, tacrolimus.
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siveness or unresponsiveness against infections, 
tumors, and self and against xenografts and 
allografts.” In this view, all immunological out-
comes are determined by the balance between 
the quantity of antigen with access to host 
lymphoid organs and the number of antigen-
specific T cells induced at these lymphoid sites. 
Moreover, the fundamental role of transplant 
immunosuppression (irradiation, drugs and 
antilymphoid antibodies) is to tilt and maintain 
a balance favoring donor leukocyte supremacy. 
With this insight, it has been possible to analyze 
what has been and what might be accomplished 
to reduce or eliminate the need for lifetime 
immunosuppression in transplant recipients.
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models of acquired tolerance in 1992, when we 
discovered a small multilineage population of 
donor leukocytes (microchimerism) in our 
long-surviving recipients of liver, kidney and 
other organs. We found that organ engraft-
ment could be explained by the “…spread of 
the transplanted organ’s lymphoid and dendritic 
cells through vascular routes to host lymphoid 
tissues,” with induction of “…responses of coex-
isting donor and recipient immune cells, each to 
the other, causing reciprocal clonal expansion, 
followed by peripheral clonal deletion”9 (Fig. 5). 
In this view, organ transplantation was a form 
of donor leukocyte chimerism–dependent 
tolerance, the completeness of which could 
be inferred from the amount of maintenance 
immunosuppression required.
Contemporaneously, Rolf Zinkernagel 
(Zurich) formally proved that the specific T cell 
response against noncytopathic microparasites 
could be exhausted and deleted, and he invoked 
clonal deletion and ‘immune ignorance’ as the 
mechanisms of tolerance to intracellular patho-
gens, which manifests clinically as a disease-
carrier state. Immune ignorance refers to the 
failure to recognize the presence of an antigen 
that does not reach host lymphoid organs; it was 
first described in the context of transplantation 
in 1967 by Clyde Barker and Rupert Billingham. 
On the premise that donor leukocytes and 
intracellular pathogens were mobile antigen 
equivalents that could induce clonal activa-
tion, exhaustion and deletion, Zinkernagel 
and I described a spectrum of transplantation 
scenarios, from outright rejection to durable 
tolerance, and their infection analogs10.
Our generalizable conclusion was that 
“…migration and localization of antigen are the 
governing factors in the immunologic respon-
experimental procedure. The resulting world-
wide stampede to develop liver-transplant 
centers was even more dramatic than that of 
kidney transplantation two decades earlier. 
In 1989, only six years later, a 17-page article 
divided between the 12 and 19 October issues 
of the New England Journal of Medicine began 
with the following statement: “The conceptual 
appeal of liver transplantation is so great that 
the procedure may come to mind as a last resort 
for virtually every patient with lethal hepatic 
disease.”
Meanwhile, at our lab in Pittsburgh, we had 
set in motion preclinical studies of tacrolimus8 
that eventually led to its substitution for cyclo-
sporine and fast-track approval by the US Food 
and Drug Administration. With tacrolimus, 
there were further improvements in survival 
with liver (Fig. 3) and, ultimately, all kinds of 
organ transplantation. In addition, tacrolimus 
elevated the liver-inclusive multivisceral trans-
plant procedures developed more than three 
decades earlier in dogs to the status of “clinical 
service.” The world’s longest-surviving multiv-
isceral recipient, now a school teacher, received 
her transplant 22 years ago (Fig. 4).
The exegesis of allo-engraftment
My colleagues and I made a connection 
between organ allo-engraftment and the mouse 
Figure 4  A multivisceral transplant recipient at 
three stages of her life.
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Figure 5  The kinetics of immunosuppression-aided exhaustion and deletion of host-versus-graft (HvG) 
and graft-versus-host (GvH) responses occurring contemporaneously in organ recipients after migration 
of the graft’s passenger leukocytes. Although host-versus-graft responses (expressed as rejection; 
upright curve) are dominant in most organ recipients, serious or lethal graft-versus-host responses 
(inverted curve), expressed as graft-versus-host disease, are not rare in recipients of lymphoid-rich 
organs such as liver and intestine. Therapeutic failure after organ or bone marrow transplantation 
implies an inability to control one or both of the responses.
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